Review article
Risks Associated With the Non-Medicinal Use of Cannabis
Dtsch Arztebl Int 2015; 112: 271-8. DOI: 10.3238/arztebl.2015.0271
; ; ; ; ;
| 1. | Grotenhermen F, Müller-Vahl K: The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109: 495–501 VOLLTEXT |
| 2. | United Nations Office on Drugs and Crime: World Drug Report 2014 (United Nations publication, Sales No. E.14.XI.7). |
| 3. | Pabst A, Kraus L, Gomes de Matos E, Piontek D: Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321–31 CrossRef |
| 4. | Europäische Beobachtungsstelle für Drogen und Drogensucht: Drogenangebot in Europa (EMCDDA). In: Europäischer Drogenbericht 2014: Trends und Entwicklungen. Luxemburg: Amt für Veröffentlichungen der Europäischen Union 2014. |
| 5. | Niesink R, van Laar MW: Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 2013; 4: 130 CrossRef MEDLINE PubMed Central |
| 6. | OCEBM Levels of Evidence Working Group: The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. www.cebm.net (last accessed on 16 December 2014). |
| 7. | Bonnet U, Scherbaum N: Cannabisbezogene Störungen. Teil II: Psychiatrische und somatische Folgestörungen und Komorbiditäten. Fortschr Neurol Psychiat 2010; 78: 1–11. |
| 8. | Crippa JA, Derenusson GN, Chagas MH, et al.: Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J 2012; 9: 7 CrossRef MEDLINE PubMed Central |
| 9. | Hall W, Degenhardt L: Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383–91 CrossRef |
| 10. | Bonnet U, Specka M, Stratmann U, Ochwadt R, Scherbaum N: Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: Cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. Drug Alcohol Depend 2014; 143: 189–97 CrossRef MEDLINE |
| 11. | Preuss UW, Watzke AB, Zimmermann J, Wong JW, Schmidt CO: Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend 2010; 106: 133–41 CrossRef MEDLINE |
| 12. | Karila L, Roux P, Rolland B: Acute and long-term effects of cannabis use: A Review. Curr Pharm 2014; 20: 4112–8 CrossRef |
| 13. | Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T: Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9: 679–89 CrossRef MEDLINE |
| 14. | Schreiner AM, Dunn ME: Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol 2012; 20: 420–29 CrossRef MEDLINE |
| 15. | Horwood L, Fergusson D, Hayatbakhsh M, et al.: Cannabis use and educational achievement: Findings from three Australasian cohort studies. Drug and Alcohol Depend 2010; 110: 247 CrossRef MEDLINE |
| 16. | Rawal SY, Tatakis DN, Tipton DA: Periodontal and oral manifestations of marijuana use. J Tenn Dent Assoc 2012; 92: 26–31 MEDLINE |
| 17. | Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA: Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167: 221–8 CrossRef MEDLINE PubMed Central |
| 18. | Volkow ND, Baler RD, Compton WM, Weiss SRB: Adverse health effects of marijuana use. N Engl J Med 2014; 370: 23 CrossRef MEDLINE |
| 19. | Pratap B, Korniyenko A: Toxic effects of marijuana on the cardiovascular system. Cardiovasc Toxicol 2012; 12: 143–8 CrossRef MEDLINE |
| 20. | Jones RT: Cardiovascular system effects of marijuana. J Clin Pharmacol 2002; 42: 58–63 CrossRef |
| 21. | Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD: Marijuana use and mortality. Am J Public Health 1997; 87: 585–90 CrossRef |
| 22. | Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S: Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis 2012; 21: 555–60 CrossRef MEDLINE |
| 23. | Tennstedt D, Saint-Remy A: Cannabis and skin diseases: Eur J Dermatol 2011; 21: 5–11 MEDLINE |
| 24. | Wu CS, Jew CP, Lu HC: Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 2011; 6: 459–80 CrossRef |
| 25. | Bari M, Battista N, Pirazzi V, Maccarrone M: The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci 2011; 16: 498–516 CrossRef |
| 26. | Tanasescu R, Constantinescu CS: Cannabinoids and the immune system: an overview. Immunobiology 2010; 215: 588–97 CrossRef MEDLINE |
| 27. | Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP: Cannabis use and mania symptoms: A systematic review and meta-analysis. J Affect Disord 2014; 23: 39–47 MEDLINE |
| 28. | Strakowski SM, DelBello MP, Fleck DE, et al.: Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64: 57–64 CrossRef MEDLINE |
| 29. | Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J: The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2014; 44: 797–810 CrossRef MEDLINE |
| 30. | Moore TH, Zammit S, Lingford-Hughes A, et al.: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28 CrossRef |
| 31. | Hall W, Degenhardt L: The adverse health effects of chronic cannabis use. Drug Test Anal 2014; 6: 39–45 CrossRef MEDLINE |
| 32. | Horwood L, Fergusson D, Coffey D, et al.: Cannabis and depression: An integrative data analysis of four Australasian cohorts. Drug Alcohol Depend 2012; 126: 369 CrossRef MEDLINE |
| 33. | Petersen KU, Thomasius R (eds.): Auswirkungen von Cannabiskonsum und -missbrauch. Lengerich, Deutschland/Rockledge, USA: Dustri, Pabst Science Publishers 2007; 79–95. |
| 34. | Baker AL, Hides L, Lubman DI: Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 2010; 71: 247–54 CrossRef MEDLINE |
| 35. | Radhakrishnan R, Wilkinson ST, D’Souza DC: Gone to pot—a review of the association between cannabis and psychosis. Front Psychiatry 2014; 5: 54 CrossRef MEDLINE PubMed Central |
| 36. | Brzozka M, Falkai P, Havemann-Reinecke U: Für Schizophrenie braucht man Drei. Suchtmed 2009; 11: 98–110. |
| 37. | Brzozka M, Fischer A, Falkai P, Havemann-Reinecke U: Acute treatment with cannabinoid receptor agonist WIN55212,2 improves prepulse inhibition in psychosocially stressed mice. Behav Brain Res 2011; 218: 280–7 CrossRef MEDLINE |
| 38. | Bossong MG, Niesink RJ: Adolescent brain maturation, the endogenous cannabinoid system, and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010; 92: 370–85. CrossRef MEDLINE |
| 39. | Bonnet U, Harries-Hedder K, Leweke FM, Schneider U, Tossmann P: AWMF-Leitlinie: Cannabis-bezogene Störungen. Fortschr Neurol Psychiatrie 2004; 72: 318–29 CrossRef MEDLINE |
| 40. | Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA: Behavioral therapies for treatment-seeking cannabis users: A meta-Analysis of randomized controlled trials. Eval Health Prof 2015; 38: 94–114 CrossRef MEDLINE |
| e1. | Cascini F, Aiello C, Di Tanna G: Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32–40 CrossRef |
| e2. | Atakan Z: Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241–54 CrossRef MEDLINE PubMed Central |
| e3. | Englund A, Morrison PD, Nottage J, et al.: Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013; 27: 19–27 CrossRef MEDLINE |
| e4. | Swift W, Wong A, Li KM, Arnold JC, McGregor IS: Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013; 24: 8. |
| e5. | United States Department of Justice, Drug enforcement administration: National drug threat assessment summary 2013; 12. www.dea.gov (last accessed on 3 March 2015). |
| e6. | Thomasius R, Weymann N, Stolle M, Petersen KU: Cannabiskonsum und -missbrauch bei Jugendlichen und jungen Erwachsenen. Auswirkungen, Komorbidität und therapeutische Hilfen. Psychotherapeut 2009; 54: 170–8 CrossRef |
| e7. | Musshoff F, Madea B: Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit 2006; 28: 155–63 CrossRefMEDLINE |
| e8. | American Psychiatric Association (APA): Diagnostic and statistical manual of mental disorders (5th edition). Arlington, VA: American Psychiatric Publishing 2013. |
| e9. | World Health Organisation (WHO): ICD-10 Classifications of mental and behavioural disorder: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation 1992. |
| e10. | Budney AJ, Hughes JR, Moore BA, Vandrey R: Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161: 1967–77 CrossRef MEDLINE |
| e11. | Budney AJ, Hughes JR: The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19: 233–8 CrossRef MEDLINE |
| e12. | Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al.: Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 2011; 115: 120–30 CrossRef MEDLINE PubMed Central |
| e13. | Anthony JC: The epidemiology of cannabis dependence. In: Roffman RA, Stephens RS (eds.): Cannabis dependence: Its nature, consequences and treatment Cambridge, UK: Cambridge University Press 2006; 58–105. |
| e14. | Hall WD, Pacula RL: Cannabis use and dependence: Public health and public policy. Cambridge, UK: Cambridge University Press 2003. |
| e15. | Tennant FS, Groesbeck CJ: Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27: 133–6 CrossRef |
| e16. | Hall WD, Solowij N: Adverse effects of cannabis. Lancet 1998; 352: 1611–16 CrossRef |
| e17. | Grover S, Basu D: Cannabis and psychopathology: update 2004. Indian J Psychiatry 2004; 46: 299–309 MEDLINE PubMed Central |
| e18. | Medina KL, Hanson KL, Schweinsburg AD, et al.: Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 2007; 13: 807–20 CrossRef MEDLINE PubMed Central |
| e19. | Solowij N, Jones KA, Rozman ME, et al.: Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology 2011; 216: 131–44 CrossRef MEDLINE |
| e20. | Meier MH, Caspi A, Abler A, et al.: Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 2012; 109: 15970–1 CrossRef MEDLINE PubMed Central |
| e21. | Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S: Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry 2013; 4: 53 MEDLINE PubMed Central |
| e22. | Cousijn J, Vingerhoets WAM, Koenders L, et al.: Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol 2013; 19: 282–93 CrossRef MEDLINE |
| e23. | Zalesky A, Solowij N, Yücel M, et al.: Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012; 135: 2245–55 CrossRef MEDLINE |
| e24. | Lee MH, Hancox RJ: Effects of smoking cannabis on lung function. Expert Rev Respir Med 2011; 5: 537–46 CrossRef MEDLINE |
| e25. | Hancox RJ, Poulton R, Ely M, et al.: Effects of cannabis on lung function: a population-based cohort study. Eur Respir J 2010; 35: 42–7 CrossRef MEDLINE PubMed Central |
| e26. | Owen KP, Sutter ME, Albertson TE: Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2014; 46: 65–81 CrossRef MEDLINE |
| e27. | Tessmer A, Berlin N, Sussman G, Leader N, Chung EC, Beezhold D: Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol 2012; 108: 282–4 CrossRef MEDLINE |
| e28. | Herkenham M, Lynn AB, Little MD, et al.: Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990; 87: 1932–6 CrossRef MEDLINE PubMed Central |
| e29. | Joshi M, Joshi A, Bartter T: Marijuana and lung diseases. Curr Opin Pulm Med 2014; 20: 173–9 CrossRef MEDLINE |
| e30. | Reid PT, Macleod J, Robertson JR: Cannabis and the lung. J R Coll Physicians Edinb 2010; 40: 328–3 CrossRef MEDLINE |
| e31. | Hezode C, Roudot-Thoraval F, Nguyen S, et al.: Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63–71 CrossRef MEDLINE |
| e32. | Galli JA, Sawaya RA, Friedenberg FK: Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4: 241–9 CrossRef |
| e33. | Gessford AK, John M, Nicholson B, Trout R: Marijuana induced hyperemesis: a case report. W V Med J 2012; 108: 20–2 MEDLINE |
| e34. | Fisher BA, Ghuran A, Vadamalai V, Antonios TF: Cardiovascular complications induced by cannabis smoking: a case report and review of the literature. Emerg Med J 2005; 22: 679–80 CrossRefMEDLINE PubMed Central |
| e35. | Reece AS: Chronic toxicology of cannabis. Clin Toxicol (Phila) 2009; 47: 517–24 CrossRef MEDLINE |
| e36. | Bachs L, Morland H: Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124: 200–3 CrossRef |
| e37. | Mateo I, Infante J, Gomez Beldarrain M, Garcia-Monco JC: Cannabis and cerebrovascular disease. Neurologia 2006; 21: 204–8 MEDLINE |
| e38. | Mukamal KJ, Maclure M, Muller JE, Mittleman MA: An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 2008; 155: 465–70 CrossRef MEDLINE PubMed Central |
| e39. | Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE: Triggering myocardial infarction by marijuana. Circulation 2001; 103: 2805–9 CrossRef |
| e40. | Muniyappa R, Sable S, Ouwerkerk R, et al.: Metabolic effects of chronic cannabis smoking. Diabetes Care 2013; 36: 2415–22 CrossRef MEDLINE PubMed Central |
| e41. | Rubio F, Quintero S, Hernandez A, et al.: Flumazenil for coma reversal in children after cannabis. Lancet 1993; 341: 1028–9 CrossRef |
| e42. | Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al.: Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 2012; 71: 215–9 CrossRef MEDLINE |
| e43. | Gray KA, Day NL, Leech S, Richardson GA: Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol 2005; 27: 439–48 CrossRef MEDLINE |
| e44. | Gray TR, Eiden RD, Leonard KE, Connors GJ, Shisler S, Huestis MA: Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem 2010; 56: 1442–50 CrossRefMEDLINE PubMed Central |
| e45. | Feng BJ, Khyatti M, Ben-Ayoub W, et al.: Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 2009; 101: 1207–12 CrossRef MEDLINE PubMed Central |
| e46. | Berthiller J, Straif K, Boniol M, et al.: Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 2008; 3: 1398–403 CrossRef MEDLINE |
| e47. | Aldington S, Harwood M, Cox B, et al.: Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008; 31: 280–6 CrossRef MEDLINE PubMed Central |
| e48. | Aldington S, Harwood M, Cox B, et al.: Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 2008; 138: 374–80 CrossRef MEDLINE PubMed Central |
| e49. | Kessler RC, Berglund P, Chiu WT, et al.: The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res 2004; 13: 69–92 CrossRef CrossRef MEDLINE |
| e50. | Lai H, Sitharthan T: Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia. Am J Drug Alcohol Abuse 2012; 38: 567 CrossRef MEDLINE |
| e51. | Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA: Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Interv Psychiatry 2014 [Epub ahead of print] CrossRef MEDLINE |
| e52. | Silberberg C, Castle D, Koethe D: Cannabis, cannabinoids, and bipolar disorder. In: Castle D, Murray R, D’Souza D (eds.): Marijuana and madness. 2nd edition. Cambridge University Press. New York 2012; 129–36. |
| e53. | Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J: Cannabis use and expression of mania in the general population. J Affect Disord 2006; 95: 103 CrossRef MEDLINE |
| e54. | Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Allebeck P: Cannabis use and depression: A longitudinal study of a national cohort of Swedish conscripts. BMC Psychiatry 2012; 12: 112 CrossRef MEDLINE MEDLINE |
| e55. | Pedersen W: Does cannabis use lead to depression and suicidal behaviours? A population-based longitudinal study. Acta Psychiatr Scand 2008; 118: 395–403 CrossRef MEDLINE |
| e56. | Fergusson D, Horwood L: Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997; 92: 279 CrossRef |
| e57. | Patton G, Harris J, Schwartz M, Bowes G: Adolescent suicidal behaviors: A population-based study of risk. Psychol Med 1997; 27: 715 CrossRef |
| e58. | Watzke AB, Schmidt CO, Zimmermann J, et al.: Personality disorders in a clinical sample of cannabis dependent young adults. Fortschr Neurol Psychiatr 2008; 76: 600–5 CrossRef MEDLINE |
| e59. | Lev-Ran S, Le FB, McKenzie K, George TP, Rehm J: Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. Psychiatry Res 2013; 209: 459–65 CrossRef MEDLINE |
| e60. | Degenhardt L, Coffey C, Romaniuk H, et al.: The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 2013; 108: 124–33 CrossRef MEDLINE |
| e61. | Stinson FS, Ruan WJ, Pickering R, Grant BF: Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006; 36: 1447–60 CrossRef MEDLINE |
| e62. | Galvez-Buccollini JA, Proal AC, Tomaselli V, et al.: Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res 2012; 139: 157–60 CrossRef MEDLINE PubMed Central |
| e63. | Giovanni M, Giuseppe DI, Gianna S, Domenico DB, Luisa DR, Massimo DG: Cannabis use and psychosis: theme introduction. Curr Pharm Des 2012; 18: 4991–8 CrossRef |
| e64. | Schafer G, Feilding A, Morgan CG, Agathangelou M, Freeman TP, Valerie Curran H: Investigating the interaction between schizotypy, divergent thinking, and cannabis use. Conscious Cogn 2012; 21: 292–8 CrossRef MEDLINE PubMed Central |
| e65. | Degenhardt L, Dierker L, Chiu WT, et al.: Evaluating the drug use „gateway“ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108: 84–97 CrossRef MEDLINE PubMed Central |
| e66. | van Gundy K, Rebellon CJ: A Life-course perspective on the “gateway hypothesis“. J Health Soc Behav 2010; 51: 244–59 CrossRef MEDLINE |
| e67. | Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA: Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Ab 2013; 40: 23–30 MEDLINE |
| e68. | Passie T, Emrich HM, Karst M, Brandt SD, Halpern JH: Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 2012; 4: 649–59 CrossRef MEDLINE |
| e69. | Greer GR, Grob, CS, Halberstadt: PTSD symptom reports of patients evaluated for the new mexico medical cannabis program. Journal of Psychoactive Drugs 2014; 46: 73–7 CrossRef MEDLINE |
| e70. | Gourlay D: Addiction and pain medicine. Pain Res Manag 2005; 10 Suppl A: 38A–43A. |
| e71. | Nazeer A, Calles JL Jr: Schizophrenia in children and adolescents. In: Greydanus DE, Calles JL Jr, Patel DR, Nazeer A, Merrick J (eds.): Clinical aspects of psychopharmacology in childhood and adolescence. New York: Nova Science 2011; 152. |
| e72. | Semple DM, McIntosh AM, Lawrie SM: Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19: 187–94 CrossRef |
| e73. | Fergusson DM, Horwood LJ, Ridder EM: Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005; 100: 354–66 CrossRef MEDLINE |
| e74. | Bender K, Tripodi S, Sarteschi C, Vaughn M: A meta-analysis of interventions to reduce adolescent cannabis use. Res Soc Work Pract 2011; 21: 153–64 CrossRef |
| e75. | Denis C, Lavie E, Fatséas M, Auriacombe M: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006; (3): CD005336. Review. Update in: Cochrane Database Syst Rev 2013; 6: CD005336 MEDLINE |
| e76. | Dutra L, Stathopoulou G, Basden SL, et al.: A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165: 179–87 CrossRef MEDLINE |
| e77. | Budney AJ, Moore BA, Rocha HL, Higgins ST: Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006; 74: 307–16 CrossRef |
| e78. | Budney AJ, Roffman R, Stephens RS, Walker D: Marijuana dependence and its treatment. Addict Sci Clin Pract 2007; 4: 4–16 CrossRef |
| e79. | Hoch E, Noack R, Henker J, et al.: Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). Eur Neuropsychopharmacol 2012; 22: 267–80 CrossRef MEDLINE |
| e80. | Hoch E, Bühringer G, Pixa A, et al.: CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend 2014; 134: 185–93 CrossRef MEDLINE |
| e81. | Kadden RM, Litt MD, Kabela-Cormier E, Petry NM: Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007; 32: 1220–36 CrossRef MEDLINE PubMed Central |
| e82. | Tait RJ, Christensen H: Internet-based interventions for young people with problematic substance use: a systematic review. Med J Aust 2010; 192: 15 MEDLINE |
| e83. | Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV: Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 116: 142–50 CrossRef MEDLINE MEDLINE |
| e84. | Allsop DJ, Copeland J, Lintzeris N: Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014; 71: 281–91 CrossRef MEDLINE |
| e85. | Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M: Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev Neurother 2008; 8: 479–91 CrossRef MEDLINE |
